




RealRate

PHARMACEUTICAL 2023

Cerevel Therapeutics Holdings Inc
Rank 261 of 471



RealRate

The First AI Rating Agency

www.realrate.ai

The relative strengths and weaknesses of Cerevel Therapeutics Holdings Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Cerevel Therapeutics Holdings Inc compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 57% points. The greatest weakness of Cerevel Therapeutics Holdings Inc is the variable Other Liabilities, reducing the Economic Capital Ratio by 99% points.

The company's Economic Capital Ratio, given in the ranking table, is 233%, being 11% points below the market average of 245%.

Input Variable	Value in 1000 USD
Assets, Current	905,651
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	72,564
Liabilities, Non-Current	31,190
Other Assets	84,704
Other Compr. Net Income	4,083
Other Expenses	160
Other Liabilities	392,830
Other Net Income	16,497
Other Revenues	0
Property and Equipment	27,467
Research and Development	280,259
Selling, General and Administrative Expense	87,589

Output Variable	Value in 1000 USD
Assets	1,017,822
Liabilities	496,584
Expenses	368,008
Revenues	0
Stockholders Equity	521,238
Net Income	-351,511
Comprehensive Net Income	-349,470
BaseVar	951,497
ECR before LimitedLiability	104%
Economic Capital Ratio	233%